Nasdaq - Delayed Quote
USD
Janus Henderson Global Life Sciences I (JFNIX)
93.44
+0.26
(+0.28%)
At close: October 30 at 8:02:44 PM EDT
Performance Overview
| Morningstar Return Rating | -- |
| YTD Return | 14.81% |
|---|---|
| 5y Average Return | 8.99% |
| Number of Years Up | 14 |
| Number of Years Down | 2 |
| Best 1Y Total Return (Oct 29, 2026) | 55.97% |
| Worst 1Y Total Return (Oct 29, 2026) | -- |
| Best 3Y Total Return | 55.97% |
| Worst 3Y Total Return | 2.75% |
Trailing Returns (%) Vs. Benchmarks
Monthly Total Returns
JFNIX
Category
- YTD
- 7.66%
- 7.95%
- 1-Month
- -4.13%
- 4.81%
- 3-Month
- -0.86%
- 7.18%
- 1-Year
- 27.76%
- 30.16%
- 3-Year
- 14.76%
- 16.10%
- 5-Year
- 8.55%
- 15.71%
- 10-Year
- 11.52%
- 15.27%
- Last Bull Market
- 27.53%
- 23.06%
- Last Bear Market
- -8.24%
- -13.88%
Annual Total Return (%) History
Year
JFNIX
Category
Past Quarterly Returns
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
|
2026
|
-3.72% | 12.80% | -0.86% | -- |
|
2025
|
0.99% | -3.76% | 8.26% | 18.66% |
|
2024
|
8.56% | 1.95% | 5.39% | -11.16% |
|
2023
|
-1.28% | 4.68% | -4.10% | 8.50% |
|
2022
|
-5.22% | -8.24% | -1.87% | 14.08% |
|
2021
|
-2.66% | 7.11% | -0.83% | 3.35% |
|
2020
|
-13.65% | 21.08% | 5.30% | 14.09% |
|
2019
|
13.87% | 2.21% | -6.56% | 18.88% |
|
2018
|
3.76% | 5.22% | 10.13% | -13.16% |
|
2017
|
11.90% | 7.20% | 4.29% | -1.95% |
Rank in Category (By Total Return)
| YTD | 62 |
| 1-Month | 78 |
|---|---|
| 3-Month | 78 |
| 1-Year | 44 |
| 3-Year | 47 |
| 5-Year | 13 |
Load Adjusted Returns
| 1-Year | 27.76% |
| 3-Year | 14.76% |
|---|---|
| 5-Year | 8.55% |
| 10-Year | 11.52% |
Performance & Risk
| YTD Return | 14.81% |
| 5y Average Return | 8.99% |
| Rank in Category (ytd) | 62 |
| % Rank in Category (ytd) | -- |
| Beta (5Y Monthly) | 0.69 |
| Morningstar Risk Rating |
Fund Overview
| Category | Health |
| Fund Family | Janus Henderson |
| Net Assets | 5.8B |
| YTD Return | 7.66% |
| Yield | 0.42% |
| Morningstar Rating | |
| Inception Date | Dec 31, 1998 |
Fund Summary
The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.
